StockData
iBio, Inc. logo

iBio, Inc. (IBIO) stock

IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$0.75+0.04 (+5.86%)

Close on Nov 17, 2026Market cap $48.11MP/E –Yield –

iBio r&d expenses

Research and development expenses are spending on new products and technology.

iBio's R&D Expenses for the twelve months ending Sep 30, 2026 was $22.74M, up 115.4% year over year. For fiscal 2026 it was $19.64M, up 136.3% from the year before. Over ten years it grew 20.1% a year on average. The highest annual figure on record is $19.64M in fiscal 2026.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Jun 30, 2026$19.64M+136.3%
FY2025Jun 30, 2025$8.31M+60.3%
FY2024Jun 30, 2024$5.19M-49.8%
FY2023Jun 30, 2023$10.33M+5.1%
FY2022Jun 30, 2022$9.83M-1.6%
FY2021Jun 30, 2021$9.99M+179.6%
FY2020Jun 30, 2020$3.57M-34.7%
FY2019Jun 30, 2019$5.47M+37.3%
FY2018Jun 30, 2018$3.99M-3.2%
FY2017Jun 30, 2017$4.12M+30.4%
FY2016Jun 30, 2016$3.16M-9.7%
FY2015Jun 30, 2015$3.50M+84.1%
FY2014Jun 30, 2014$1.90M-44.7%
FY2013Jun 30, 2013$3.43M-31.1%
FY2012Jun 30, 2012$4.98M+61.5%
FY2011Jun 30, 2011$3.08M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ3 2026Sep 30, 2026$6.65M+87.3%
Q4 FY2026CQ2 2026Jun 30, 2026$8.56M+165.5%
Q3 FY2026CQ1 2026Mar 31, 2026$3.25M+70.7%
Q2 FY2026CQ4 2025Dec 31, 2025$4.28M+128.0%
Q1 FY2026CQ3 2025Sep 30, 2025$3.55M+172.0%
Q4 FY2025CQ2 2025Jun 30, 2025$3.22M+182.8%
Q3 FY2025CQ1 2025Mar 31, 2025$1.91M+110.8%
Q2 FY2025CQ4 2024Dec 31, 2024$1.88M+22.3%
Q1 FY2025CQ3 2024Sep 30, 2024$1.31M-18.7%
Q4 FY2024CQ2 2024Jun 30, 2024$1.14M-51.6%
Q3 FY2024CQ1 2024Mar 31, 2024$904.00K-65.8%
Q2 FY2024CQ4 2023Dec 31, 2023$1.54M-44.8%
Q1 FY2024CQ3 2023Sep 30, 2023$1.61M-37.0%
Q4 FY2023CQ2 2023Jun 30, 2023$2.36M-33.9%
Q3 FY2023CQ1 2023Mar 31, 2023$2.64M-19.2%
Q2 FY2023CQ4 2022Dec 31, 2022$2.78M-10.3%
Q1 FY2023CQ3 2022Sep 30, 2022$2.55M+17.9%
Q4 FY2022CQ2 2022Jun 30, 2022$3.56M+50.0%
Q3 FY2022CQ1 2022Mar 31, 2022$3.27M+75.7%
Q4 FY2021CQ2 2021Jun 30, 2021$3.10M+431.2%
Q3 FY2021CQ1 2021Mar 31, 2021$2.16M+97.4%
Q2 FY2021CQ4 2020Dec 31, 2020$2.37M+167.3%
Q1 FY2021CQ3 2020Sep 30, 2020$1.86M+90.6%
Q4 FY2020CQ2 2020Jun 30, 2020$583.00K-64.1%
Q3 FY2020CQ1 2020Mar 31, 2020$1.10M-24.6%
Q2 FY2020CQ4 2019Dec 31, 2019$888.00K-30.2%
Q1 FY2020CQ3 2019Sep 30, 2019$977.00K-13.1%
Q4 FY2019CQ2 2019Jun 30, 2019$1.62M+55.9%
Q3 FY2019CQ1 2019Mar 31, 2019$1.45M+50.4%
Q2 FY2019CQ4 2018Dec 31, 2018$1.27M+28.2%
Q1 FY2019CQ3 2018Sep 30, 2018$1.12M+14.1%
Q4 FY2018CQ2 2018Jun 30, 2018$1.04M-6.3%
Q3 FY2018CQ1 2018Mar 31, 2018$966.00K-15.0%
Q2 FY2018CQ4 2017Dec 31, 2017$993.00K-5.3%
Q1 FY2018CQ3 2017Sep 30, 2017$985.00K+20.1%
Q4 FY2017CQ2 2017Jun 30, 2017$1.11M–
Q3 FY2017CQ1 2017Mar 31, 2017$1.14M–
Q2 FY2017CQ4 2016Dec 31, 2016$1.05M–
Q1 FY2017CQ3 2016Sep 30, 2016$820.00K–

More iBio figures

See a number that looks wrong?